Advertisement

BMC Pediatrics

, 19:424 | Cite as

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive diseases in China: a meta-analysis

  • Jinjian Fu
  • Rongsong Yi
  • Yongjiang Jiang
  • Shaolin Xu
  • Peixu Qin
  • Zhuoxin LiangEmail author
  • Jichang ChenEmail author
Open Access
Research article
  • 331 Downloads
Part of the following topical collections:
  1. Infection

Abstract

Background

To summarize information about invasive pneumococcal disease (IPD) among children in mainland China.

Methods

Sixteen eligible studies were included in this systematic review and the random effect model was used to estimate the pool prevalence of IPD.

Results

The most predominant serotypes circulating in children were 19F (27.7, 95% confidence interval (95% CI): 17.7–37.6%), 19A (21.2%, 16.4–26.1%), 14 (16.5%, 12.8–20.1%), 6B (8.6%, 5.2–10.8%) and 23F (7.3%, 5.2–9.5%). The serotype coverage of the available pneumococcal conjugate vaccines PCV7, PCV10, and PCV13 was 60.8% (52.5–69.4%), 65.1% (57.7–72.4%), and 90.0% (87.1–92.8%), respectively. The pooled antibiotic resistance rates of Streptococcus pneumoniae revealed a resistance to penicillin prevalence rate of 32.0% (12.1–51.9%). Approximately 94.4% (90.7–98.1%) and 92.3% (87.4–97.3%) of isolates were resistant to erythromycin and clindamycin. eBURST analysis revealed great diversity among isolates, with 102 sequence types (STs) for 365 isolates. The major predominant clonal complexes (CCs) were CC271 (43.6%, 159/365), CC876 (13.4%, 49/365), CC81 (5.2%, 19/365), and CC90 (4.1%, 15/365). Long-term and regional surveillance of S. pneumoniae is necessary.

Conclusions

Based on our pooled results showing that PCV13 coverage of the reported serotypes was 90% and that most serotypes contributed to the distribution of antibiotic-resistant isolates, implementation of PCV13 into the Chinese Expanded Program on Immunizations (EPI) would achieve health benefits in Chinese children.

Keywords

Invasive pneumococcal disease Children China Serotype Streptococcus pneumonia 

Abbreviations

CC

Clonal complexes

CIs

Confidence intervals

CLSI

Clinical and Laboratory Standards Institute

CNKI

China National Knowledge Infrastructure

EPI

Expanded Program on Immunization

HR

Hazard ratio

IPD

Invasive pneumococcal disease

MLST

Multilocus sequence typing

PCV

Pneumococcal conjugate vaccine

PNSP

Penicillin-non-susceptible pneumococci

S. pneumonia

Streptococcus pneumonia

STs

Sequence types

Background

Streptococcus pneumonia (S. pneumoniae) is one of the most prominent pathogens, causing mild to life-threatening invasive diseases due to its well-known capsule pathogenicity [1]. It has been reported that approximately 1 million people die of pneumococcal diseases annually, most of whom are children under 5 years old [2, 3, 4]. Pneumococcal conjugate vaccines (PCVs) targeting 7, 10, or 13 of more than 90 serotypes of S. pneumoniae have been successively introduced to reduce the burden of invasive pneumococcal disease (IPD) in vaccinated children in developed countries [5, 6]. In fact, it has been reported that after licensing PCV13, pneumococcal diseases of any cause, but especially those caused by PCV13 minus PCV7 serotypes, were further decreased across each age group in the UK [7].

In China, S. pneumoniae is one of the most common pathogens and can cause infectious diseases, especially pneumonia, in children under 5 years of age [8]. PCV7 was first introduced in mainland China in 2008 [9] but due to its high price was not included as part of the national immunization schedule. Because of its high cost in the the private market [10], and the vaccine may not be available to some low-income families, especially in western China. But a model predicted that every year, 112,629 cases of pneumococcal-related disease could be prevented in Shanghai if the PCV7 vaccine could be introduced [11]. After employing PCV7, another multicenter study conducted in Shanghai in 2013 reported that the serotype coverage of PCV7, − 10, and − 13 was 58.6, 59.4 and 85.1%, respectively [12].

Both genetic background and capsular type contribute to the ability of S. pneumoniae to cause invasive diseases [13, 14]. The aim of this study was to obtain a systematic estimate of the serotypes of S. pneumonia and their antibiotic resistances and to determine clonal types causing IPD in mainland China.

Material and methods

Literature search strategy

The design and construction of this systematic review was performed and completed according to the PRISMA checklist [13]. (see Additional file 1). The following databases were searched: PubMed, MEDLINE, EMBASE, WanFang Data (http://www.wanfangdara.com.cn), and the China National Knowledge Infrastructure (CNKI) database (http://cnki.net/). The time frame was January 2000 to September 2016. The keywords for the literature search were “Streptococcus pneumoniae OR invasive pneumococcal disease OR pneumococcal conjugate vaccine”, “children OR school children OR 0-18 years”, “serotype OR capsular type” and “China OR Chinese”.

Eligibility criteria

Two reviewers (RS Yi and JC Chen) independently identified eligible studies and extracted data based on the following criteria: (1) the publication language was Chinese or English, (2) the study participants were generally Chinese children aged from 0 to 18 years, (3) the study provided invasive pneumococcal serotypes and/or specific patterns of antibiotic sensitivity, and (4) the serotyped pneumococcal isolates were obtained from normally sterile sites (e.g., blood, cerebrospinal fluid, and pleural fluid). Exclusion criteria were as follows: (1) the study data included adult patients, and specific infection data about children could not be extracted; (2) the data were not regarding invasive pneumococcal diseases; (3) the data did not provide specific serotypes and/or specific patterns of antibiotic sensitivity; (4) the studies were reviews, lectures, or editorials; or (5) the studies were duplicates published in both Chinese and English (in this case, only the English-language studies were included).

Data extraction

The data were screened and reviewed independently by two authors (RS Yi and JC Chen) according to the inclusion and exclusion criteria, and the following information was extracted: first author’s name; study location; district; study period; publication year; age group; positive strains; serotyping method; serotypes; serotype coverage of PCV7, − 10, and − 13; and antibiotic resistance patterns of the positive cases and total cases.

Statistical analysis

Statistical analyses were performed using Stata statistical software version 13.0 (Stata corporation LP, College Station, Texas, USA). The pooled relevant serotypes and antibiotic resistance prevalence and their corresponding 95% confidence intervals (CIs) were evaluated using the DerSimonian and Laird random-effects model [15]. The Cochrane chi-square (x2) test and quantification with the I2 statistic were used to calculate the source of heterogeneity [16, 17]. Begg’s funnel plots and Egger’s test (significant at P ≤ 0.1) were used to assess publication bias [18].

Results

Characteristics of the studies

The literature search and study selection process in the final analysis is shown in Fig. 1. A total of 358 articles were identified. After screening the titles and abstracts and based on our inclusion/exclusion criteria, 24 studies were selected for further investigation. Studies involving adult or mixed populations were excluded, and 16 studies, with 2146 patients, were selected for the final meta-analysis [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34].
Fig. 1

Flow chart of the study selection process

The main characteristics of the studies are listed in Table 1. The first study of invasive pneumococcal diseases among children was conducted in 8 centers in 2005–2006 [30]. Only 3 investigations were conducted before PCV7 was introduced in mainland China [19, 21, 30]. The geographical characteristics of the included surveys revealed that 5 were conducted in northern China [21, 29, 31, 32, 34]and 8 in southern China [20, 22, 23, 25, 26, 27, 28, 33]. All samples evaluated in the included studies were subjected to the Quellung reaction method, except for 4 samples for which the multiple polymerase chain reaction (MPCR) method was applied. The ages of the children investigated ranged from 0 to 14 years.
Table 1

Characteristic of included studies

Author

Study location

District

Study period

Publication year

Age group

Total strains

Positive strains

Serotyping method

Xue L et al. [19]

11 centers

national

2006–2008

2010

< 14 years

171

171

Quellung reaction

Ma X et al. [20]

Shenzhen

south

2009–2012

2013

< 14 years

87

87

Quellung reaction

Liu C et al. [21]

Shenyang

north

2009–2011

2013

< 5 years

61

61

Quellung reaction

Ding Y et al. [22]

Suzhou

south

2011–2013

2015

< 14 years

79

79

MPCR

Kang L et al. [23]

Chongqing

south

2010–2013

2016

< 11 years

51

51

MPCR

Liu C et al. [24]

15 centers

national

2005–2008

2010

< 11 years

148

81

Quellung reaction

Xu F et al. [25]

Nnajing

south

2007–2010

2012

< 14 years

48

48

Quellung reaction

Lu C et al. [26]

Shenzhen

south

2010–2013

2015

< 14 years

74

74

Quellung reaction

Zhou K et al. [27]

Nanjing

south

2009–2013

2015

< 14 years

51

51

Quellung reaction

Song X et al. [28]

Taizhou

south

2010–2014

2015

< 5 years

322

322

Quellung reaction

Wang Y et al. [29]

Hebei

north

2014

2016

< 8 years

43

43

MPCR

Lyu S et al. [30]

Beijing

north

2013–2014

2016

< 14 years

21

21

Quellung reaction

Liu Y et al. [31]

8 centers

national

2005–2006

2008

< 5 years

451

31

Quellung reaction

Dong F et al. [32]

Beijing

north

2013–2014

2016

< 14 years

195

21

Quellung reaction

Li J et al. [33]

Beijing

north

2012–2014

2016

< 14 years

21

21

Quellung reaction

Miao D et al. [34]

Nanjing

south

2007–2011

2016

< 14 years

323

56

MPCR

MPCR multiple polymerase chain reaction

Serotypes of pneumococcal strains isolated from IPD pediatric patients

Tables 2 and 3 present the pooled serotype distributions of S. pneumoniae among Chinese children aged from 0 to 14 years and under 5 years, respectively.
Table 2

Pooled serotype distribution of Streptococcus pneumoniae among Chinese children

Variable

Included studies

Positive cases

Total cases

Rate (%) (95% CI)

Total IPD

16

1218

2146

10.0 (5.0–14.9)

1

3

9

155

4.9 (1.5–8.3)

3

1

4

56

7.1 (0.4–13.9)

4

1

1

61

1.6 (1.5–4.8)

5

6

13

368

2.6 (1.0–4.2)

6A

1

1

21

4.8 (4.3–13.9)

6B

3

96

1006

8.0 (5.2–10.8)

7F

3

8

173

4.5 (1.4–7.6)

9 V

7

23

357

5.7 (3.3–8.1)

14

11

140

796

16.5 (12.8–20.1)

18C

15

5

171

2.9 (0.45.4)

19A

15

241

1197

21.2 (16.4–26.1)

19F

13

419

1197

27.7 (17.7–37.6)

23F

14

94

1062

7.3 (5.2–9.5)

PCV7 serotype coverage

14

752

1197

60.8 (52.2–69.4)

PCV10 serotype coverage

14

784

1197

65.1 (57.7–72.4)

PCV13 serotype coverage

14

1030

1197

90.0 (87.1–92.8)

Table 3

Pooled serotype distribution of Streptococcus pneumoniae among Chinese children under 5 years old

Variable

Included studies

Positive cases

Total cases

Rate (%)(95% CI)

Total IPD

5

517

590

 

1

1

2

61

3.3 (1.2–7.7)

4

1

1

61

1.6 (1.5–4.8)

5

2

5

67

7.0 (0.9–13.0)

6A

1

1

36

2.8 (2.6–8.1)

6B

3

53

523

7.8 (1.0–14.7)

9 V

2

4

97

3.8 (0.0–7.7)

14

4

49

268

15.1 (6.6–23.6)

19A

5

115

590

25.8 (15.5–36.0)

19F

5

242

590

26.4 (4.0–48.8)

23F

5

56

590

8.4 (5.5–11.2)

PCV7 serotype coverage

5

403

590

53.0 (32.7–73.3)

PCV10 serotype coverage

5

412

590

57.4 (39.7–75.2)

PCV13 serotype coverage

5

517

590

83.5 (72.8–94.1)

Sixteen studies [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] reported serotypes for invasive pneumococcal diseases. A total of 18 different serotypes were identified among 1218 strains, with the most predominant being 19F. The pooled prevalence of the 19F serotype was 27.7% (17.7–37.6%), followed by the 19A serotype at 21.2% (16.4–26.1%), the 14 serotype at 16.5% (12.8–20.1%), the 6B serotype at 8.0% (5.2–10.8%) and the 23F serotype at 7.3% (5.2–9.5%). Of the 1218 isolates, 752, 784, and 1030 were identified as serotypes included in the coverage of PCV7, − 10, and − 13, respectively. The serotype coverage rates were 60.8% (52.2–69.4%), 65.1% (57.7–72.4%), and 90.0% (87.1–92.8%) for PCV7, − 10, and − 13, respectively.

Only 5 studies [19, 21, 24, 28, 30] reported IPD strains from children under 5 years of age. A total of 13 different serotypes were identified among 517 strains, with 19F being the most predominant serotype. The pooled prevalence of the 19F serotype was 26.4% (4.0–48.8%), followed by the 19A serotype at 25.8% (15.5–36.0%), the 14 serotype at 15.1% (16.6–23.6%), the 23F serotype at 8.4% (5.5–11.2%) and the 6B serotype at 7.8% (1.0–14.7%). Of the 517 isolates, 403, 412, and 517 were identified from children under 5 years old as serotypes included in the coverage of PCV7, − 10, and − 13, respectively. The serotype coverage rates were 53.0% (32.7–73.3%), 57.4% (39.7–75.2%), and 83.5% (72.8–94.1%) for PCV7, − 10, and − 13, respectively. Significant heterogeneity (P values all < 0.001) was found for each serotype and the coverage of PCV7, − 10, − 13.

Antibiotic resistance patterns of IPD isolates

Tables 4 and 5 show the antibiotic resistance patterns of IPD isolates among Chinese children. Ten studies reported antibiotic resistance patterns among the 0–14 year-old group. All of the isolates were highly resistant to erythromycin, clindamycin, tetracycline, and sulfamethoxazole, with resistance rates of 94.4% (90.7–98.1%), 92.3% (87.4–97.3%), 83.7% (75.1–92.2%), and 74.4% (64.5–84.4%), respectively. The reported penicillin-non-susceptible S. pneumoniae (PNSP) rate was 74.6% (23.3–71.9%), and the resistance rate to penicillin was 32.0% (12.1–51.9%).
Table 4

Pooled antibiotic resistance rates of Streptococcus pneumoniae among Chinese children

Antibiotics

Included studies

Positive cases

Total cases

Rate(%) (95% CI)

Penicillin

9

488

1345

32.0 (12.1–51.9)

Amoxicillin clavulanic acid

5

199

1026

16.1 (2.1–30.0)

Amoxicillin

2

61

159

37.5 (27.6–47.4)

Ceftriaxone

7

239

1216

14.7 (6.1–23.3)

Chloramphenicol

7

129

910

11.4 (7.2–15.6)

Erythromycin

10

1259

1396

94.4 (90.7–98.1)

Clindamycin

8

1066

1204

92.3 (87.4–97.3)

Sulfamethoxazole

10

1052

1396

74.4 (64.5–84.4)

Tetracycline

9

1098

1335

83.7 (75.1–92.2)

PNSP

10

693

1396

74.6 (23.3–71.9)

PNSP Penicillin-Non-susceptible Streptococcus pneumonia

Table 5

Pooled antibiotic resistance rates of Streptococcus pneumoniae among Chinese children under 5 years old

Antibiotics

Included studies

Positive cases

Total cases

Rate(95% CI)

Penicillin

3

407

834

45.1 (18.5–71.7)

Amoxicillin clavulanic acid

3

195

834

23.3 (20.4–26.2)

Ceftriaxone

3

211

834

22.5 (15.3–29.7)

Chloramphenicol

1

79

451

17.5 (14.0–21.0)

Erythromycin

3

713

834

87.8 (74.8–99.3)

Clindamycin

3

705

834

84.2 (71.2–97.1)

Sulfamethoxazole

3

660

834

83.9 (68.6–99.2)

Tetracycline

2

631

773

78.9 (45.6–99.3)

PNSP

3

520

834

60.0 (17.2–89.4)

PNSP Penicillin-Non-susceptible Streptococcus pneumoniae

The antibiotic resistance patterns of IPD in the under 5 years-old group were similar to those of the 0–14 years-old group. Predominant resistance was observed for erythromycin at 87.8% (74.8–99.3%), followed by clindamycin at 84.2% (71.2–97.1%), sulfamethoxazole at 83.9% (68.6–99.2%), and tetracycline at 78.9% (45.6–99.3%). The PNSP rate was 60.6% (17.2–89.4%) and the penicillin resistance rate 45.1% (18.5–71.7%). Significant heterogeneity (P values all < 0.001) was reported for each antibiotic resistance rate.

Genetic background of IPD strains isolated from children in mainland China

A total of 102 STs were reported in the 365 IPD isolates for which multilocus sequence typing (MLST) was conducted. The five most highly predominant STs for all reported IPD isolates were ST271 (20.82%, 76/365), ST320 (19.73%, 72/365), ST876 (12.33%, 45/365), ST81 (3.84%, 14/365) and ST90 (3.56%, 13/365), which were mainly related to serotypes 19F, 14, 19A, and 23F. The five most predominant STs among the 102 reported accounted for 60.28% of the isolates.

MLST data analysis performed using eBURST v3 grouped the isolates into 4 CCs. ST81, ST90, ST876 and ST271 were confirmed as probable founder genotypes (Fig. 2). Eleven single-locus variants (SLVs) were found in ST271. Figure 3 shows high genetic diversity of IPD isolates from mainland China based on the global S. pneumoniae genetic background.
Fig. 2

Population snapshot of pooled Streptococcus pneumoniae data based on eBURST analysis. One spot corresponds to the number of pneumococcal isolates with the same ST

Fig. 3

Pooled Streptococcus pneumoniae data based on global database screening using eBURST analysis. One spot corresponds to the number of pneumococcal isolates with the same ST. The yellow spot indicates the major clone found in our study. The pink spot indicates clones found in our study

Discussion

Epidemiological and clinical studies have shown that invasive pneumococcal diseases caused by S. pneumoniae is a major public health burden. Based on a systematic review of the literature, Chen et al [35] reported that approximately 700,000 children are diagnosed with pneumococcal disease each year and that approximately 30,000 deaths are attributed to S. pneumoniae; moreover, over 50% of children with pneumonia in China died because of this pathogen. The high pneumococcal disease burden makes the investigation and evaluation of S. pneumoniae serotypes important for providing evidence and guidance for the use of vaccines and antibiotics targeting the pathogen.

Our study revealed that the predominant serotypes circulating among Chinese children were 19F, 19A, 14, 6B and 23F. For children under 5 years old, the predominant serotypes were 19F, 19A, 14, 23F and 6B. A global serotype project confirmed that serotype 14 was the most prevalent cause of IPD among children under five in every region, including Asia; however, this systematic review did not include studies from mainland China, which contains the largest population of children under 5 years of age in the world [36]. In that report, seven serotypes (1, 5, 6A, 6B, 14, 19F and 23F) accounted for over 50% of IPD in every region, including Asia, and our results demonstrated that 14, 19F, 6B, 23F and 19A accounted for 80.7 and 73.5% of all IPD in Chinese children 0–14 years and children under 5 years of age, respectively. The major serotype patterns of S. pneumoniae in mainland China were consistent with the ANSORP study, which revealed that 19F, 23F, 19A, 14 and 6B were the major serotypes in Asia [37]. Serotype 1 is reported as one of the 5 most common serotypes in many developing countries such as in South Africa Kenya and in Philippines [37, 38, 39], but this serotype was infrequency in our study, which may revealed that the serotype distribution of S.pneumoniae was varied geographically [40].

Pooled analysis of multiple surveillance sites revealed that vaccine-serotype and overall IPD rates declined consistently and significantly after PCV7 introduction, and this effect was still observed after 7 years [41]. Unfortunately, these promising effects may not represent the important public health implications in some countries that did not implement routine immunization with PCVs, such as China [10]. Although the PCV7 vaccine was imported into and licensed in China in 2008, this vaccine has not yet been included in the Chinese Expanded Program on Immunizations (EPI) [42]. The PCV7 vaccine was removed from the market in 2015, though new vaccines, such as PCV10 and PCV13, have not yet been employed in the Chinese market, making the situation even worse [10].

Our analyses revealed serotype coverage rates for PCV7, − 10, and − 13 of 60.8, 65.1, and 90.0%, respectively, for IPD among Chinese children. A cohort and case-control study conducted in Europe [43] revealed that after the 13-valent pneumococcal conjugate vaccination was introduced, the overall IPD incidence declined in both vaccinated (hazard ratio, HR: 0.24, 95% CI: 0.14–0.40) and unvaccinated children (HR, 95% CI: 0.22, 0.09–0.55). The direct effect of PCV13 against vaccine serotypes was as high as 95%. According to two studies conducted in China, only 9.9% or 10.1% of children received a dose of PCV7 [10, 44]. Such low vaccination may not produce satisfactory results for reducing the burden of pneumococcal diseases. A Markov simulation model conducted by Mo et al [45] showed that PCV13 can reduce IPD by 31.3% and pneumonia by 15.3% in mainland China.

The high pneumococcal disease burden and the largest population baseline of children in China means that the cost-effectiveness of launching PCV7 or higher valence vaccines would improve if the government introduced the vaccines into the EPI. According to the mathematical model conducted by Hu et al [46], a policy of universal PCV7 vaccination among infants in China would prevent approximately 10.8 million cases of disease and save 636,371 lives over 10 years, largely due to the indirect effectiveness of the vaccine on the unvaccinated population.

Global multi-region studies have revealed that the highest antibiotic resistance to S. pneumoniae was consistently found in Asia [37], and the ANSORP reports demonstrated that S. pneumoniae isolates from mainland China had the highest antibiotic resistance rates [37]. Indeed, it was reported that S. pneumoniae isolated from Chinese children had the highest antibiotic resistance rates [31]; the most predominant resistance, 96.4%, was to the antibiotic erythromycin, followed by tetracycline and sulfamethoxazole. Our study revealed S. pneumoniae to be most frequently resistant to erythromycin, followed by clindamycin, tetracycline, and sulfamethoxazole, consistent with previous study and the ANSORP study [37].

Our findings indicated a pooled penicillin resistance rate to S. pneumoniae of 32.0% and a PNSP of 74.6%, which was much higher than the ANSORP study results but consistent with a study conducted in Beijing that revealed a total non-susceptibility rate of penicillin of 91.5% if based on an oral breakpoint of Clinical and Laboratory Standards Institute (CLSI) [31]. The limitation of our study is that we cannot estimate the resistance rate to penicillin based on revised CLSI breakpoints, as most of the included studies did not report the adaptation of the breakpoints. However, our results were partially consistent with the ANSORP study, which reported a resistance rate to penicillin of 60.0% for meningeal isolates [37].

The snapshot from eBURST showed a great diversity among IPD strains isolated in mainland China. The predominant clones were CC271, CC876, CC81 and CC90. CC271 was the most predominant CC, and the inclusion of 11 STs, such as ST271, ST320, ST236, and ST4664, accounted for 43.6% of all the included isolates from the literature. Several studies have confirmed that this clone became prevalent prior to the introduction of PCV7 and spread rapidly among both adults and children in China [44]. The widespread use of antibiotics has also been implicated in the emergence of serotype 19A and 19F isolates in both communities and hospitals. The two serotypes of the isolates were reported to be multidrug resistant and carriers of the ermB and mefA genes, making the situation even worse [47, 48].

A significantly increased risk of CC271 strains, which caused IPD in our study, is anticipated among children and is in agreement with existing trends in the literature regarding transmission [49]. ST236, namely the original Taiwan19F-14 clone, was the major international antibiotic-resistant strain. In addition, long-term monitoring data revealed that ST271 and ST320 evolved rapidly and replaced ST236 due to their higher fitness and that they were becoming well established in local regions of China [47]. It was also reported that CC271 is prevalent in Asian countries, such as Japan and Korea, due to the introduction of PCV7 [50, 51]. After implementation of PCV7, non-vaccine-related serotypes, such as 19A, circulated among pediatric groups. This serotype was reported to be multidrug resistant due to PCV7 implementation and antibiotic selection pressure. The high prevalence of CC271 clones was consistent with the high penicillin non-susceptibility rate found in IPD isolates pooled in this study.

According to a multicenter study conducted in China, ST320, ST271, and ST876 were the prevalent types among IPD isolates collected from children [52]. Another study showed that the CC876 prevalence increased from 0% in 1997–2000 to 96.4% in 2010–2012 in China, and the most important findings of this study were that this clone had high non-susceptibility rates to β-lactam antibiotics [53].

CC81 comprises ST81 (Spain23F-1, 5.2%, 19/365), and CC90 comprises ST90 (Spain6B-2, 4.1%, 15/365), which were also found at lower frequencies in this study. These complexes are listed as internationally spread resistant CCs [31].

Conclusions

This is the first study to pool data for invasive pneumococcal diseases among children. The study has several limitations. First, the studies pooled were highly heterogeneous. Second, the studies included did not report the specific breakpoint from CLSI, and therefore we could not estimate the actual resistance of meningeal isolates. Long-term monitoring is required to estimate antibiotic resistance and serotype distributions in an effort to provide a policy to introduce a new PCV vaccine for Chinese children.

Notes

Acknowledgements

Not applicable.

Authors’ contributions

This study was based on original clinical work supported by JF, RY, YJ, SX, PQ, ZL and JC. This study was conceived and monitored, the data were analyzed, and the paper was written by JF and RY. The collection of data was assisted by JF, SX and PQ. The manuscript was revised by ZL and JC. All of authors approved the final content of this manuscript.

Funding

This manuscript was funded by Guangxi Medical and Health Self-funding Project (No Z2014379, No Z20180022) and Liuzhou Science and Technology Bureau Project (No 2014 J030422, 2018BJ10504, 2018BJ10502). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Liuzhou Maternity and Child Healthcare Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

12887_2019_1722_MOESM1_ESM.doc (54 kb)
Additional file 1. PRISMA 2009 checklist.

References

  1. 1.
    Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Child health epidemiology reference group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969–87.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO child health epidemiology reference group. WHO estimates of the causes of death in children. Lancet. 2005;365:1147–52.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    World Health Organization, Immunization Vaccines and Biologicals. Estimated Hib and pneumococcal deaths for children under 5 years of age. 2008. Available at: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/2015). Accessed 29 Dec 2016.Google Scholar
  4. 4.
    O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Moreira M, Castro O, Palmieri M, Efklidou S, Castagna S, Hoet B. A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in southern Europe (2009-2016). Hum Vaccin Immunother. 2016;20:0.Google Scholar
  7. 7.
    Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16(1):77.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Yao KH, Yang YH. Streptococcus pneumoniae diseases in Chinese children: past, present and future. Vaccine. 2008;26(35):4425–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Bao Y, Wang Q, Yao K, Xie G, Gao W, Huang L, Liu X, Zhu C, Chen H, Wang H, Shen K, Zheng Y, Yang Y. The changing phenotypes and genotypes of invasive pneumococcal isolates from children in Shenzhen during 2013-2017. Vaccine. 2019.  https://doi.org/10.1016/j.vaccine.2019.09.069 CrossRefGoogle Scholar
  10. 10.
    Boulton ML, Ravi NS, Sun X, Huang Z, Wagner AL. Trends in childhood pneumococcal vaccine coverage in Shanghai, China, 2005-2011: a retrospective cohort study. BMC Public Health. 2016;16:109.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Hu S, Shi Q, Song S, Du L, He J, Chen CI, Caldwell R, Wang B, Roberts CS. Estimating the Cost-Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Shanghai, China. Value Health Reg Issues. 2014 May;3:197-204PubMedCrossRefGoogle Scholar
  12. 12.
    Pan F, Han L, Huang W, Tang J, Xiao S, Wang C, et al. Serotype distribution, antimicrobial susceptibility, and molecular epidemiology of Streptococcus pneumoniae isolated from children in Shanghai, China. PLoS One. 2015;10(11):e0142892.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    http://www.prismastatement.org/statement.htm. Available at August 12, 2019.
  14. 14.
    Deng X, Arya G, Memari N, Mackenzie R, MacMullin G, Low DE, et al. Genetic analysis of invasive pneumococcal isolates from children in Ontario, Canada, 2007-2012. Pediatr Infect Dis J. 2015;34(6):594–8.PubMedCrossRefGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRefGoogle Scholar
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Xue L, Yao K, Xie G, Zheng Y, Wang C, Shang Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates that cause invasive disease among Chinese children. Clin Infect Dis. 2010;50(5):741–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Ma X, Zhao R, Ma Z, Yao K, Yu S, Zheng Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children’s hospital. PLoS One. 2013;8(6):e67507.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Liu C, Xiong X, Xu W, Sun J, Wang L, Li J. Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age. PLoS One. 2013;8(1):e54254.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ding Y, Geng Q, Tao Y, Lin Y, Wang Y, Black S, et al. Etiology and epidemiology of children with acute otitis media and spontaneous otorrhea in Suzhou, China. Pediatr Infect Dis J. 2015;34(5):e102–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Kang LH, Liu MJ, Xu WC, Cui JJ, Zhang XM, Wu KF, et al. Molecular epidemiology of pneumococcal isolates from children in China. Saudi Med J. 2016;37(4):403–13.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Liu CL, Zhao CJ, Liu YD, Wang H. Study of serotype distribution, antimicrobial resistance patterns and molecular epidemiology in 148 isolates of invasive Streptococcus pneumoniae. Natl Med J China. 2010;90(22):1565–70.Google Scholar
  25. 25.
    Xu F, Chi FL, Tan H, Liu XM, Cao T, Pan W, et al. Study on serotype distribution in 48 isolates of invasive Streptococcus pneumoniae with which children infected. Chin J Biochem Pharm. 2012;33(6):909–11.Google Scholar
  26. 26.
    Lu C. Serotype distribution in invasive Streptococcus pneumoniae from hospitalized pediatric patients. Int J Lab Med. 2015;36(7):990–2.Google Scholar
  27. 27.
    Zhou K, Xie GJ, Wang XW, Xu F, Yao KH. Clinical characteristic of invasive pneumococcal disease and its serotype distribution. Chin J Nosocomiol. 2015;25(15):3392–4.Google Scholar
  28. 28.
    Song XQ, Duan DR, Lai JX. Serotype and drug resistance of Streptococcus pneumoniae from preschool children with suppurative otitis media. Chin J Microecol. 2015;27(7):819–23.Google Scholar
  29. 29.
    Wang YT, Guo YH, Wang Q, Jia ZY, Zhang WC, Sun YQ, et al. Serotype analysis of 43 strains of invasive Streptococcus pneumoniae isolated in Hebei Province, 2014. Chin J Vaccines Immun. 2016;22(1):6–9.Google Scholar
  30. 30.
    Lyu S, Yao KH, Dong F, Xu BP, Liu G, Wang Q, et al. Vaccine serotypes of Streptococcus pneumoniae with high-level antibiotic resistance isolated more frequently seven years after the licensure of PCV7 in Beijing. Pediatr Infect Dis J. 2016;35(3):316–21.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis. 2008;61(3):256–63.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Dong F, Zhen JH, Wang Y, Xu BP, Wang Q, Liu G, et al. Analysis of features of streptococcus pneumoniae isolated from the cultured bacteria sample in pediatric patients. Chin J Pract Pediatr. 2016;31(3):201–5.Google Scholar
  33. 33.
    Li J, Ma LJ, Shi W, Zhou L, Xu WJ, Yao KH, et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolated in hospitalized children. Chin J Lab Med. 2015;38(9):622–6.Google Scholar
  34. 34.
    Miao DQ, Xu F, Li JQ, Liu JJ, Shao ZQ, Zhu T, et al. Serotype distribution of streptococcus pneumoniae from children's clinical isolates in Nanjing. China Med Eng. 2016;24(2):12–5.Google Scholar
  35. 35.
    Chen Y, Deng W, Wang SM, Mo QM, Jia H, Wang Q, et al. Burden of pneumonia and meningi-tis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review. PLoS One. 2011;6:e27333.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, ANSORP Study Group, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian network for surveillance of resistant pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012;56(3):1418–26.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    du Plessis M, Allam M, Tempia S, Wolter N, de Gouveia L, von Mollendorf C, Jolley KA, Mbelle N, Wadula J, Cornick JE, Everett DB, McGee L, Breiman RF, Gladstone RA, Bentley SD, Klugman KP, von Gottberg A. Phylogenetic analysis of invasive serotype 1 pneumococcus in South Africa, 1989 to 2013. J Clin Microbiol. 2016;54(5):1326–34.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang L, Fu J, Liang Z, Chen J. Prevalence and serotype distribution of nasopharyngeal carriage of Streptococcus pneumoniae in China: a meta-analysis. BMC Infect Dis. 2017;17(1):765.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Yu H, Yang W, Varma JK. To save children’s lives, China should adopt an initiative to speed introduction of pneumonia vaccines. Health Aff. 2012;31(11):2545–53.CrossRefGoogle Scholar
  43. 43.
    Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, et al. Working Group for Surveillance of the Pneumococcal Invasive Disease in Navarra. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill. 2016;21:14.CrossRefGoogle Scholar
  44. 44.
    Zheng J, Cao L, Guo S, Wang LAK, Yu W, et al. Survey of the current situation of category 2 vaccines in Chinese children aged 1 to 2 years. Chin J Vaccine Immun. 2012;18(3):233–7 [In Chinese].Google Scholar
  45. 45.
    Mo X, Gai Tobe R, Liu X, Mori R. Cost-effectiveness and health benefits of pediatric 23-valent pneumococcal polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine and forecasting 13-valent pneumococcal conjugate vaccine in China. Pediatr Infect Dis J. 2016;35(11):e353–61.PubMedCrossRefGoogle Scholar
  46. 46.
    Hu S, Shi Q, Chen CI, Caldwell R, Wang B, Du L, et al. Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV7) in China. Int J Infect Dis. 2014;26:116–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Zhao C, Zhang F, Chu Y, Liu Y, Cao B, Chen M, et al. Phenotypic and genotypic characteristic of invasive pneumococcal isolates from both children and adult patients from a multicenter surveillance in China 2005-2011. PLoS One. 2013;8(12):e82361.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Bowers JR, Driebe EM, Nibecker JL, Wojack BR, Sarovich DS, Wong AH, et al. Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona. BMC Microbiol. 2012;12:12.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26(6):461–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, et al. Kansai community acquired pneumococcal pneumonia study group. High prevalence of multidrug-resistant pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan. Clin Microbiol Infect. 2009;15(11):1039–45.PubMedCrossRefGoogle Scholar
  51. 51.
    Eun BW, Kim SJ, Cho EY, Lee J, Choi EH, Lee HJ. Genetic structure of Streptococcus pneumoniae isolated from children in a tertiary care university hospital, in Korea, 1995 to 2005. Diagn Microbiol Infect Dis. 2010;68(4):345–51.PubMedCrossRefGoogle Scholar
  52. 52.
    Qian J, Yao K, Xue L, Xie G, Zheng Y, Wang C, et al. Diversity of pneumococcal surface protein A (PspA) and relation to sequence typing in Streptococcus pneumoniae causing invasive disease in Chinese children. Eur J Clin Microbiol Infect Dis. 2012;31(3):217–23.PubMedCrossRefGoogle Scholar
  53. 53.
    He M, Yao K, Shi W, Gao W, Yuan L, Yu S, et al. Dynamics of serotype 14 Streptococcus pneumoniae population causing acute respiratory infections among children in China (1997-2012). BMC Infect Dis. 2015;15:266.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Jinjian Fu
    • 1
    • 2
  • Rongsong Yi
    • 3
  • Yongjiang Jiang
    • 4
  • Shaolin Xu
    • 1
  • Peixu Qin
    • 1
  • Zhuoxin Liang
    • 5
    • 6
    Email author
  • Jichang Chen
    • 4
    Email author
  1. 1.Department of Laboratory MedicineLiuzhou Maternity and Child Health Care HospitalLiuzhouChina
  2. 2.Department of Laboratory MedicineAffiliated Rong’an of Liuzhou Maternity and Child Health Care HospitalLiuzhouChina
  3. 3.Department of PediatricLiuzhou Maternity and Child Health Care HospitalLiuzhouChina
  4. 4.Department of NeonatologyLiuzhou Maternity and Child Health Care HospitalLiuzhouChina
  5. 5.Department of Pediatric Intensive Care UnitLiuzhou Maternity and Child Health Care HospitalLiuzhouChina
  6. 6.Department of PediatricAffiliated Rong’an of Liuzhou Maternity and Child Health Care HospitalLiuzhouChina

Personalised recommendations